MX2017011882A - Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides. - Google Patents

Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides.

Info

Publication number
MX2017011882A
MX2017011882A MX2017011882A MX2017011882A MX2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A
Authority
MX
Mexico
Prior art keywords
myeloid
antibody
compositions
lymphoid
methods
Prior art date
Application number
MX2017011882A
Other languages
English (en)
Inventor
Y Park Christopher
Shiu- Sah Chung Stephen
Tavakkoli Montreh
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017011882A publication Critical patent/MX2017011882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Se describen, composiciones y métodos para el tratamiento de malignidades hematopoyéticas y linfoides entre las que se incluyen leucemias mielógenas agudas (AML) por CD99+, síndromes mielodisplásicos (MDS) y neoplasmas de células T. Las composiciones descritas comprenden uno o más anticuerpos que (a) se unen al dominio extracelular de CD99, (b) se ligan con CD99 expresado en la superficie de células malignas mieloides o linfoides, (c) estimulan el rematado/agrupamiento/agregación de CD99 expresado en la superficie de células malignas mieloides o linfoides, y (d) inducen la apoptosis en células malignas mieloides o linfoides por CD99+ ligadas a anticuerpos y la consiguiente citotoxicidad de las mismas. Los métodos descritos comprenden administrar un anticuerpo anti-CD99, ya sea solo o en combinación con uno o más componentes adicionales tales como un agente de movilización, un agente para bloquear la transmigración, y un agente quimioterapéutico tal como daunorrubicina, idarrubicina, citarabina, 5-azacitidina, y decitabina.
MX2017011882A 2015-03-18 2016-03-18 Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides. MX2017011882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135119P 2015-03-18 2015-03-18
PCT/US2016/023303 WO2016149682A2 (en) 2015-03-18 2016-03-18 Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies

Publications (1)

Publication Number Publication Date
MX2017011882A true MX2017011882A (es) 2018-04-20

Family

ID=56919925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011882A MX2017011882A (es) 2015-03-18 2016-03-18 Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides.

Country Status (9)

Country Link
EP (1) EP3271399A4 (es)
JP (1) JP2018511311A (es)
KR (1) KR20170136535A (es)
CN (1) CN107614531A (es)
AU (1) AU2016232719A1 (es)
BR (1) BR112017019856A2 (es)
CA (1) CA2980038A1 (es)
MX (1) MX2017011882A (es)
WO (1) WO2016149682A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737391A4 (en) * 2018-01-08 2022-03-23 H. Lee Moffitt Cancer Center & Research Institute, Inc. COMPOSITIONS AND METHODS TARGETED AGAINST CD99-EXPRESSING CANCER
EP3801771A1 (en) * 2018-06-04 2021-04-14 Diatheva S.r.l. Anti-cd99 diabody or igg antibody and uses thereof
IT201800005991A1 (it) * 2018-06-04 2019-12-04 Complesso anticorpale ed usi derivati

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
WO2006024169A1 (en) * 2004-09-01 2006-03-09 Hemax Genome Inc. Genes of the pseudoautosomal region 1 and their use in the diagnosis, treatment and prevention of autoimmune diseases
CN101437539B (zh) * 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
WO2010056351A2 (en) * 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
PL2477648T3 (pl) * 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2015069935A1 (en) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes

Also Published As

Publication number Publication date
CA2980038A1 (en) 2016-09-22
KR20170136535A (ko) 2017-12-11
WO2016149682A2 (en) 2016-09-22
AU2016232719A1 (en) 2017-10-12
JP2018511311A (ja) 2018-04-26
WO2016149682A3 (en) 2017-01-26
CN107614531A (zh) 2018-01-19
BR112017019856A2 (pt) 2018-05-29
EP3271399A2 (en) 2018-01-24
EP3271399A4 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
JOP20190013A1 (ar) أجسام مضادة لـ (تي آي ام -3)
PH12016501411B1 (en) Bifunctional cytotoxic agents
PH12015502087B1 (en) Newcastle disease viruses and uses thereof
NZ722326A (en) Tricyclic compounds as anticancer agents
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2014190163A3 (en) Combination therapy for mds
PE20181292A1 (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso
MY177989A (en) Lna oligonucleotide carbohydrate conjugates
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
PH12019502477A1 (en) Use of anti cd70 antibody argx-10 treat acute myeloid leukemia
UY36075A (es) Derivados de tubulisina
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
MX2017011882A (es) Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides.
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2016081773A3 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2016008304A (es) Usos de oligouronatos en el tratamiento de cancer.
EP3490548A4 (en) ADMINISTRATION OF HYPOXIA-ACTIVATED DRUGS IN COMBINATION WITH IMMUNOMODULATORS FOR THE TREATMENT OF CANCER
EP3413912A4 (en) COMPOSITIONS AND METHODS FOR TARGETING SIGNALING OF ACTIVIN TO TREAT CANCER
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).